Proteome analysis of human substantia nigra in Parkinson's disease

Proteome Science

Volumn 6, Issue , 2008, Pages

  Werner, Cornelius J ^a,b   Heyny von Haussen, Roland ^c   Mall, Gerhard ^c   Wolf, Sabine ^d  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c KLINIKUM DARMSTADT   (Germany)

^d DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ADENOSINE; ADENOSINE TRIPHOSPHATASE; ADENOSYLHOMOCYSTEINASE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE DEHYDROGENASE; BETA TUBULIN; BUCLADESINE; COLLAPSIN RESPONSE MEDIATOR PROTEIN; CYTOCHROME C OXIDASE; FACTOR A; FERRITIN; GALECTIN 1; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE AMMONIA LIGASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE P1; ISOMERASE; LACTATE DEHYDROGENASE; LIPOCORTIN 5; PROTEIN 14 3 3; PROTEIN SH3; PROTEIN SUBUNIT; PROTEOME; RAB PROTEIN; RETINOL BINDING PROTEIN; RHO FACTOR; SORCIN;

AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRON METABOLISM; MALE; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PATHOGENESIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN METHYLATION; SUBSTANTIA NIGRA;

EID: 40749153440     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-6-8     Document Type: Article

References (97)

1. Goedert M Parkinson's disease and other alpha-synucleinopathies Clin Chem Lab Med 2001, 39:308-312. 10.1515/CCLM.2001.047 11388653
2. Braak H Ghebremedhin E Rub U Bratzke H Del Tredici K Stages in the development of Parkinson's disease-related pathology Cell Tissue Res 2004, 318:121-134. 10.1007/s00441-004-0956-9 15338272
3. Strickland D Bertoni JM Parkinson's prevalence estimated by a state registry Mov Disord 2004, 19:318-323. 10.1002/mds.10619 15022187
4. Findley L Aujla M Bain PG Baker M Beech C Bowman C Holmes J Kingdom WK MacMahon DG Peto V Playfer JR Direct economic impact of Parkinson's disease: A research survey in the united kingdom Mov Disord 2003, 18:1139-1145. 10.1002/mds.10507 14534917
5. The Parkinson Study Group Mortality in DATATOP: A multicenter trial in early Parkinson's disease Ann Neurol 1998, 43:318-325. 10.1002/ ana.410430419 9506548
6. Langston JW Ballard P Tetrud JW Irwin I Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 1983, 219:979-980. 10.1126/science.6823561 6823561
7. Betarbet R Sherer TB MacKenzie G Garcia-Osuna M Panov AV Greenamyre JT Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat Neurosci 2000, 3:1301-1306. 10.1038/81834 11100151
8. Miklossy J Doudet DD Schwab C Yu S McGeer EG McGeer PL Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys Exp Neurol 2006, 197:275-283. 10.1016/j.expneurol.2005.10.034 16336966
9. Polymeropoulos MH Lavedan C Leroy E Ide SE Dehejia A Dutra A Pike B Root H Rubenstein J Boyer R Stenroos ES Chandrasekharappa S Athanassiadou A Papapetropoulos T Johnson WG Lazzarini AM Duvoisin RC Di Iorio G Golbe LI Nussbaum R Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 1997, 276:2045-2047. 10.1126/ science.276.5321.2045 9197268
10. Kruger R Kuhn W Muller T Woitalla D Graeber M Kosel S Przuntek H Epplen JT Schols L Riess O Ala30pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat Genet 1998, 18:106-108. 10.1038/ng0298-106 9462735
11. Kitada T Asakawa S Hattori N Matsumine H Yamamura Y Minoshima S Yokochi M Mizuno Y Shimizu N Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 1998, 392:605-608. 10.1038/33416 9560156
12. Leroy E Boyer R Auburger G Leube B Ulm G Mezey E Harta G Brownstein MJ Jonnalagada S Chernova T Dehejia A Lavedan C Gasser T Steinbach PJ Wilkinson KD Polymeropoulos MH The ubiquitin pathway in Parkinson's disease Nature 1998, 395:451-452. 10.1038/26652 9774100
13. Barzilai A Melamed E Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease Trends Mol Med 2003, 9:126-132. 10.1016/S1471-4914(03)00020-0 12657434
14. Jenner P Olanow CW The pathogenesis of cell death in Parkinson's disease Neurology 2006, 66:S24-36. 16717250
15. Basso M Giraudo S Corpillo D Bergamasco B Lopiano L Fasano M Proteome analysis of human substantia nigra in Parkinson's disease Proteomics 2004, 4:3943-3952. 10.1002/pmic.200400848 15526345
16. Jin J Hulette C Wang Y Zhang T Pan C Wadhwa R Zhang J Proteomic identification of a stress protein, mortalin/mthsp70/grp75: Relevance to Parkinson disease Mol Cell Proteomics 2006, 5:1193-1204. 10.1074/ mcp.M500382-MCP200 16565515
17. Berggren K Chernokalskaya E Steinberg TH Kemper C Lopez MF Diwu Z Haugland RP Patton WF Background-free, high sensitivity staining of proteins in one- and two-dimensional sodium dodecyl sulfate-polyacrylamide gels using a luminescent ruthenium complex Electrophoresis 2000, 21:2509-2521. 10.1002/ 1522-2683(20000701)21:12<2509::AID-ELPS2509>3.0.CO;2-9 10939466
18. Braak H Braak E Pathoanatomy of Parkinson's disease J Neurol 2000 247(Suppl 2):II3-10. 10991663 10.1007/PL00007758
19. Sandmann-Keil D Braak H Zur postmortalen Diagnose des idiopathischen Morbus Parkinson Pathologe 2005, 26:214-220. 10.1007/s00292-004-0722-5 15538572
20. Fountoulakis M Hardmeier R Hoger H Lubec G Postmortem changes in the level of brain proteins Exp Neurol 2001, 167:86-94. 10.1006/ exnr.2000.7529 11161596
21. Kim RY Gasser R Wistow GJ Mu-crystallin is a mammalian homologue of agrobacterium ornithine cyclodeaminase and is expressed in human retina Proc Natl Acad Sci USA 1992, 89:9292-9296. 50112 1384048 10.1073/ pnas.89.19.9292
22. Franzen B Yang Y Sunnemark D Wickman M Ottervald J Oppermann M Sandberg K Dihydropyrimidinase related protein-2 as a biomarker for temperature and time dependent post mortem changes in the mouse brain proteome Proteomics 2003, 3:1920-1929. 10.1002/pmic.200300535 14625854
23. Inagaki N Chihara K Arimura N Menager C Kawano Y Matsuo N Nishimura T Amano M Kaibuchi K CRMP-2 induces axons in cultured hippocampal neurons Nat Neurosci 2001, 4:781-782. 10.1038/90476 11477421
24. van Heusden GPH 14-3-3 proteins: Regulators of numerous eukaryotic proteins IUBMB Life 2005, 57:623-629. 16203681
25. Healy DG Abou-Sleiman PM Casas JP Ahmadi KR Lynch T Gandhi S Muqit MMK Foltynie T Barker R Bhatia KP Quinn NP Lees AJ Gibson JM Holton JL Revesz T Goldstein DB Wood NW UCH-L1 is not a Parkinson's disease susceptibility gene Ann Neurol 2006, 59:627-633. 10.1002/ana.20757 16450370
26. Choi J Levey AI Weintraub ST Rees HD Gearing M Chin L Li L Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases J Biol Chem 2004, 279:13256-13264. 10.1074/jbc.M314124200 14722078
27. Zhang L Shimoji M Thomas B Moore D Yu S Marupudi N Torp R Torgner I Ottersen O Dawson T Dawson V Mitochondrial localization of the Parkinson's disease related protein DJ-1: Implications for pathogenesis Hum Mol Genet 2005, 14:2063-2073. 10.1093/hmg/ddi211 15944198
28. Terrisse L Poirier J Bertrand P Merched A Visvikis S Siest G Milne R Rassart E Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients J Neurochem 1998, 71:1643-1650. 9751198
29. Thomas EA Laws SM Sutcliffe JG Harper C Dean B McClean C Masters C Lautenschlager N Gandy SE Martins RN Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: No relation to apolipoprotein E expression or genotype Biol Psychiatry 2003, 54:136-141. 10.1016/S0006-3223(02)01976-5 12873803
30. Ordonez C Navarro A Perez C Astudillo A Martinez E Tolivia J Apolipoprotein D expression in substantia nigra of Parkinson disease Histol Histopathol 2006, 21:361-366. 16437381
31. Reutelingsperger CP van Heerde WL Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis Cell Mol Life Sci 1997, 53:527-532. 10.1007/s000180050067 9230931
32. Walton M Sirimanne E Reutelingsperger C Williams C Gluckman P Dragunow M Annexin V labels apoptotic neurons following hypoxia-ischemia Neuroreport 1997, 8:3871-3875. 10.1097/00001756-199712220-00007 9462458
33. Vermes I Steur EN Reutelingsperger C Haanen C Decreased concentration of annexin V in parkinsonian cerebrospinal fluid: Speculation on the underlying cause Mov Disord 1999, 14:1008-1010. 10.1002/ 1531-8257(199911)14:6<1008::AID-MDS1015>3.0.CO;2-E 10584677
34. Riederer P Sofic E Rausch WD Schmidt B Reynolds GP Jellinger K Youdim MB Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains J Neurochem 1989, 52:515-520. 10.1111/ j.1471-4159.1989.tb09150.x 2911028
35. Dexter DT Carayon A Vidailhet M Ruberg M Agid F Agid Y Lees AJ Wells FR Jenner P Marsden CD Decreased ferritin levels in brain in Parkinson's disease J Neurochem 1990, 55:16-20. 10.1111/j.1471-4159.1990.tb08814.x 2355217
36. Connor JR Snyder BS Arosio P Loeffler DA LeWitt P A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains J Neurochem 1995, 65:717-724. 7616228
37. Zecca L Gallorini M Schunemann V Trautwein AX Gerlach M Riederer P Vezzoni P Tampellini D Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: Consequences for iron storage and neurodegenerative processes J Neurochem 2001, 76:1766-1773. 10.1046/j.1471-4159.2001.00186.x 11259494
38. Gotz ME Double K Gerlach M Youdim MB Riederer P The relevance of iron in the pathogenesis of Parkinson's disease Ann N Y Acad Sci 2004, 1012:193-208. 10.1196/annals.1306.017 15105267
39. Perry TL Godin DV Hansen S Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci Lett 1982, 33:305-310. 10.1016/ 0304-3940(82)90390-1 7162692
40. Sofic E Lange KW Jellinger K Riederer P Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease Neurosci Lett 1992, 142:128-130. 10.1016/0304-3940(92)90355-B 1454205
41. Sian J Dexter DT Lees AJ Daniel S Agid Y Javoy-Agid F Jenner P Marsden CD Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann Neurol 1994, 36:348-355. 10.1002/ana.410360305 8080242
42. Bharath S Hsu M Kaur D Rajagopalan S Andersen JK Glutathione, iron and Parkinson's disease Biochem Pharmacol 2002, 64:1037-1048. 10.1016/ S0006-2952(02)01174-7 12213603
43. Sian J Dexter DT Lees AJ Daniel S Jenner P Marsden CD Glutathione-related enzymes in brain in Parkinson's disease Ann Neurol 1994, 36:356-361. 10.1002/ana.410360306 8080243
44. Damier P Hirsch EC Zhang P Agid Y Javoy-Agid F Glutathione peroxidase, glial cells and Parkinson's disease Neuroscience 1993, 52:1-6. 10.1016/ 0306-4522(93)90175-F 8433802
45. Baez S Segura-Aguilar J Widersten M Johansson AS Mannervik B Glutathione transferases catalyse the detoxication of oxidized metabolites (O-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes Biochem J 1997,324 (Pt 1):25-28. 1218396 9164836
46. Abel EL Bammler TK Eaton DL Biotransformation of methyl parathion by glutathione S-transferases Toxicol Sci 2004, 79:224-232. 10.1093/toxsci/ kfh118 15103050
47. Menegon A Board PG Blackburn AC Mellick GD Le Couteur DG Parkinson's disease, pesticides, and glutathione transferase polymorphisms Lancet 1998, 352:1344-1346. 10.1016/S0140-6736(98)03453-9 9802272
48. Kelada SN Stapleton PL Farin FM Bammler TK Eaton DL Smith-Weller T Franklin GM Swanson PD Longstreth WTJ Checkoway H Glutathione S-transferase M1, T1, and P1 polymorphisms and Parkinson's disease Neurosci Lett 2003, 337:5-8. 10.1016/S0304-3940(02)01286-7 12524158
49. Whitworth AJ Theodore DA Greene JC Benes H Wes PD Pallanck LJ Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a drosophila model of Parkinson's disease Proc Natl Acad Sci USA 2005, 102:8024-8029. 1142368 15911761 10.1073/pnas.0501078102
50. Ishikawa T Casini AF Nishikimi M Molecular cloning and functional expression of rat liver glutathione-dependent dehydroascorbate reductase J Biol Chem 1998, 273:28708-28712. 10.1074/jbc.273.44.28708 9786866
51. Li Y Oliveira SA Xu P Martin ER Stenger JE Scherzer CR Hauser MA Scott WK Small GW Nance MA Watts RL Hubble JP Koller WC Pahwa R Stern MB Hiner BC Janko Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease Hum Mol Genet 2003, 12:3259-3267. 10.1093/hmg/ddg357 14570706
52. Schmuck EM Board PG Whitbread AK Tetlow N Cavanaugh JA Blackburn AC Masoumi A Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of omega class glutathione transferase variants: Implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseases Pharmacogenet Genomics 2005, 15:493-501. 15970797
53. Mazzocco M Maffei M Egeo A Vergano A Arrigo P Di Lisi R Ghiotto F Scartezzini P The identification of a novel human homologue of the SH3 binding glutamic acid-rich (SH3BGR) gene establishes a new family of highly conserved small proteins related to thioredoxin superfamily Gene 2002, 291:233-239. 10.1016/S0378-1119(02)00602-9 12095696
54. Yin L Xiang Y Zhu D Yan N Huang R Zhang Y Wang D Crystal structure of human sh3bgrl protein: The first structure of the human SH3BGR family representing a novel class of thioredoxin fold proteins Proteins 2005, 61:213-216. 10.1002/prot.20523 16080146
55. Chinta SJ Rajagopalan S Butterfield DA Andersen JK In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease Neurosci Lett 2006, 402:137-141. 10.1016/j.neulet.2006.03.056 16644116
56. Power JHT Shannon JM Blumbergs PC Gai W Nonselenium glutathione peroxidase in human brain: Elevated levels in Parkinson's disease and dementia with Lewy bodies Am J Pathol 2002, 161:885-894. 1867235 12213717
57. Manevich Y Fisher AB Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism Free Radic Biol Med 2005, 38:1422-1432. 10.1016/j.freeradbiomed.2005.02.011 15890616
58. Ralat LA Manevich Y Fisher AB Colman RF Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transferase Pi with activity changes in both enzymes Biochemistry 2006, 45:360-372. 10.1021/bi0520737 16401067
59. Bandmann O Davis MB Marsden CD Harding AE Sequence of the superoxide dismutase 1 (SOD 1) gene in familial Parkinson's disease J Neurol Neurosurg Psychiatry 1995, 59:90-91. 7608718
60. Farin FM Hitosis Y Hallagan SE Kushleika J Woods JS Janssen PS Smith-Weller T Franklin GM Swanson PD Checkoway H Genetic polymorphisms of superoxide dismutase in Parkinson's disease Mov Disord 2001, 16:705-707. 10.1002/mds.1153 11481695
61. Choi J Rees HD Weintraub ST Levey AI Chin L Li L Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases J Biol Chem 2005, 280:11648-11655. 10.1074/ jbc.M414327200 15659387
62. Banati RB Daniel SE Blunt SB Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease Mov Disord 1998, 13:221-227. 10.1002/mds.870130205 9539333
63. Pantazis NJ Zaheer A Dai D Zaheer S Green SH Lim R Transfection of c6 glioma cells with glia maturation factor upregulates brain-derived neurotrophic factor and nerve growth factor: Trophic effects and protection against ethanol toxicity in cerebellar granule cells Brain Res 2000, 865:59-76. 10.1016/S0006-8993(00)02194-6 10814733
64. Lim R Zaheer A Kraakevik JA Darby CJ Oberley LW Overexpression of glia maturation factor in c6 cells promotes differentiation and activates superoxide dismutase Neurochem Res 1998, 23:1445-1451. 10.1023/ A:1020715126326 9814556
65. McGraw J Oschipok LW Liu J Hiebert GW Mak CFW Horie H Kadoya T Steeves JD Ramer MS Tetzlaff W Galectin-1 expression correlates with the regenerative potential of rubrospinal and spinal motoneurons Neuroscience 2004, 128:713-719. 10.1016/j.neuroscience.2004.06.075 15464279
66. Sasaki T Hirabayashi J Manya H Kasai K Endo T Galectin-1 induces astrocyte differentiation, which leads to production of brain-derived neurotrophic factor Glycobiology 2004, 14:357-363. 10.1093/glycob/cwh043 14693917
67. Clemen CS Herr C Hovelmeyer N Noegel AA The lack of annexin A7 affects functions of primary astrocytes Exp Cell Res 2003, 291:406-414. 10.1016/ j.yexcr.2003.07.012 14644162
68. Munch G Kuhla B Luth H Arendt T Robinson SR Anti-AGEing defences against Alzheimer's disease Biochem Soc Trans 2003, 31:1397-1399. 14641072
69. Kuhla B Boeck K Schmidt A Ogunlade V Arendt T Munch G Luth H Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains Neurobiol Aging 2006.
70. Vander Jagt DL Hunsaker LA Methylglyoxal metabolism and diabetic complications: Roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase Chem Biol Interact 2003 143-144:341-351. 10.1016/S0009-2797(02)00212-0
71. Jain SK Glutathione and glucose-6-phosphate dehydrogenase deficiency can increase protein glycosylation Free Radic Biol Med 1998, 24:197-201. 10.1016/S0891-5849(97)00223-2 9436631
72. Munch G Luth HJ Wong A Arendt T Hirsch E Ravid R Riederer P Crosslinking of alpha-synuclein by advanced glycation endproducts - an early pathophysiological step in lewy body formation? J Chem Neuroanat 2000, 20:253-257. 10.1016/S0891-0618(00)00096-X 11207423
73. Dalfó E Portero-Otín M Ayala V Martínez A Pamplona R Ferrer I Evidence of oxidative stress in the neocortex in incidental Lewy body disease J Neuropathol Exp Neurol 2005, 64:816-830. 16141792
74. Webster J Urban C Berbaum K Loske C Alpar A Gartner U de Arriba SG Arendt T Munch G The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal Neurotox Res 2005, 7:95-101. 15639802
75. McCaffery P Drager UC High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system Proc Natl Acad Sci USA 1994, 91:7772-7776. 44484 8052659 10.1073/pnas.91.16.7772
76. Maring JA Deitrich RA Little R Partial purification and properties of human brain aldehyde dehydrogenases J Neurochem 1985, 45:1903-1910. 10.1111/j.1471-4159.1985.tb10550.x 4056797
77. Esterbauer H Zollner H Lang J Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions Biochem J 1985, 228:363-373. 1144994 3160340
78. Yoritaka A Hattori N Uchida K Tanaka M Stadtman ER Mizuno Y Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease Proc Natl Acad Sci USA 1996, 93:2696-2701. 39693 8610103 10.1073/pnas.93.7.2696
79. Galter D Buervenich S Carmine A Anvret M Olson L ALDH1 mRNA: Presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia Neurobiol Dis 2003, 14:637-647. 10.1016/j.nbd.2003.09.001 14678778
80. Grunblatt E Mandel S Jacob-Hirsch J Zeligson S Amariglo N Rechavi G Li J Ravid R Roggendorf W Riederer P Youdim MBH Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes J Neural Transm 2004, 111:1543-1573. 10.1007/ s00702-004-0212-1 15455214
81. Noy N Retinoid-binding proteins: Mediators of retinoid action Biochem J 2000 348(Pt 3):481-495. 1221089 10839978 10.1042/0264-6021:3480481
82. Krezel W Ghyselinck N Samad TA Dupe V Kastner P Borrelli E Chambon P Impaired locomotion and dopamine signaling in retinoid receptor mutant mice Science 1998, 279:863-867. 10.1126/science.279.5352.863 9452386
83. Zetterstrom RH Solomin L Jansson L Hoffer BJ Olson L Perlmann T Dopamine neuron agenesis in nurr1-deficient mice Science 1997, 276:248-250. 10.1126/science.276.5310.248 9092472
84. Beasley CL Pennington K Behan A Wait R Dunn MJ Cotter D Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes Proteomics 2006, 6:3414-3425. 10.1002/pmic.200500069 16637010
85. Morel N Dedieu J Philippe J Specific sorting of the A1 isoform of the V-H+ATPase a subunit to nerve terminals where it associates with both synaptic vesicles and the presynaptic plasma membrane J Cell Sci 2003, 116:4751-4762. 10.1242/jcs.00791 14600261
86. Bohnen N Albin R Koeppe R Wernette K Kilbourn M Minoshima S Frey K Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease J Cereb Blood Flow Metab 2006, 26:1198-1212. 16421508
87. Tehlivets O Hasslacher M Kohlwein SD S-adenosyl-L-homocysteine hydrolase in yeast: Key enzyme of methylation metabolism and coordinated regulation with phospholipid synthesis FEBS Lett 2004, 577:501-506. 10.1016/j.febslet.2004.10.057 15556636
88. Muller T Woitalla D Hauptmann B Fowler B Kuhn W Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease Neurosci Lett 2001, 308:54-56. 10.1016/ S0304-3940(01)01972-3 11445284
89. Muller T Woitalla D Fowler B Kuhn W 3-OMD and homocysteine plasma levels in parkinsonian patients J Neural Transm 2002, 109:175-179. 10.1007/ s007020200013 12075857.
90. Ozkan S Colak O Kutlu C Ertan M Alatas O Plasma homocysteine levels in pergolide-treated Parkinson disease patients Clin Neuropharmacol 2004, 27:163-165. 10.1097/01.wnf.0000136890.78887.b9 15319701
91. Valkovic P Benetin J Blazicek P Valkovicova L Gmitterova K Kukumberg P Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients Parkinsonism Relat Disord 2005, 11:253-256. 10.1016/ j.parkreldis.2005.01.007 15878587 patients
92. Lamberti P Zoccolella S Iliceto G Armenise E Fraddosio A de Mari M Livrea P Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients Mov Disord 2005, 20:69-72. 10.1002/ mds.20261 15390046
93. O'Suilleabhain PE Oberle R Bartis C Dewey RBJ Bottiglieri T Diaz-Arrastia R Clinical course in Parkinson's disease with elevated homocysteine Parkinsonism Relat Disord 2006, 12:103-107. 10.1016/ j.parkreldis.2005.10.002 16368256
94. Tribl F Gerlach M Marcus K Asan E Tatschner T Arzberger T Meyer H Bringmann G Riederer P "Subcellular proteomics" of neuromelanin granules isolated from the human brain Mol Cell Proteomics 2005, 4:945-957. 10.1074/mcp.M400117-MCP200 15851778
95. Bradford MM A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3 942051
96. Matrix Science - MASCOT http://www.matrixscience.com/cgi/ search_form.pl?FORMVER=2&SEARCH=PMF
97. The Rockefeller University, Laboratory of Mass Spectrometry and Gaseous Ion Chemistry - ProFound http://prowl.rockefeller.edu/prowl-cgi/ profound.exe